Research

Anaplastic Large Cell Lymphoma Treatment - Phase III

Comparison of Two Combination Chemotherapy Regimens with Either Vincristine or Vinblastine in Treating Patients with Advanced Anaplastic Large Cell Lymphoma

Protocol Description

This Children's Oncology Group Phase III study evaluates whether substituting vinblastine for the standard drug vincristine in treating patients with anaplastic large-cell lymphoma (ALCL) will result in more patients achieving and staying in remission. Vinblastine has already been shown to achieve remission in patients with ALCL that has relapsed. Through the use of random assignment in this study, researchers hope to assess whether administering vinblastine in the initial treatment will work better than the standard treatment of chemotherapy using vincristine.

Eligibility Criteria

Male and female patients under the age of 21 and diagnosed with ALCL will be considered.
Boys: Up through age 20
Girls: Up through age 20

Requirements
Participants will undergo standard medical and organ function tests throughout the length of this study. Through random assignment, participants will be administered either vincristine or vinblastine chemotherapy as part of their regimen. There will be 15, 21-day cycles of consolidation chemotherapy for both regimens.
Visits: Number of visits is variable depending on the patient’s response; some treatments may require hospitalization.
Duration: About 1 year with follow-up expected for 10 years

Status: Open

Source of Support
Children’s Oncology Group (Study ANHL0131)
National Cancer Institute

Additional Resources
Children’s Oncology Group CureSearch
Study Description at National Institutes of Health